Source: Eur Respir J 2004; 24 : 644-648
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Wasserfallen J-B., Erard V., Cometta A., Calandra T., Lamy O.. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 2004; 24 : 644-648

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Combination versus monotherapy for nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 50-55 Year: 2007 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Source: Eur Respir J 2007; 30: 525-531 Year: 2007 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006